Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
The leading professional organisation for medical oncology
An onsite and online congress
Register for this live discussion based on the widely used ESMO Guidelines and help patients with the best care options
Stay updated with the most recent research in mCRC and submit your questions to the experts
Register now for ESMO Sarcoma & GIST 2022, onsite in Milan, and online on 31 January – 2 February!
The ESMO-MCBS is a validated and reproducible tool to assess the magnitude of clinical benefit for cancer medicines.
Discover the latest data for management of aHCC, with encouraging results in NSCLC
On the ESMO Perspectives, Elena Garralda discusses the latest achievements in precision oncology
The collaborative study shows significant gaps in low- and middle-income countries
The ESMO Immuno-Oncology Congress 2021, the European platform dedicated to the development and use of immunotherapies for cancer treatment, will be held as an onsite and online congress.
Efficacy was evaluated in AMPECT study in patients with locally advanced unresectable or metastatic malignant PEComa
Withdrawal concerns application to use Cervarix in individuals from the age of 9 years for the prevention of head and neck cancers
ESMO has announced today that the 2021 ESMO Award for Immuno-oncology is presented to Hervé Fridman
The results from a randomised, phase III DAWNA-1 study with a new, orally administered, selective CDK4/6 inhibitor
ESMO would like to thank Dr Gustavo A. Lopez for his help in validation of translation in Spanish language
Results from the first prospective study showing that patients with HER2-amplified metastatic colorectal cancer identified by ctDNA genotyping benefit from dual-HER2 blockade similarly to patients identified by conventional tissue analysis
It is intended for the treatment of patients with advanced NSCLC with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy
The COSMIC-312 trial met its primary endpoint of progression-free survival, but interim overall survival results need further exploration
In the first interim analysis of the ORIENT-31 trial, progression-free survival was slightly improved in patients who progressed after EGFR TKI, but mature results are needed to confirm whether combination therapy represents a new therapeutic option in this setting
Risk assessment and alternative fluoropyrimidine regimens are the main changes in the Pan-Asian adapted ESMO Clinical Practice Guidelines, reinforcing ESMO’s commitment in the region
The Pan-Asian adaptation of the EHNS-ESMO-ESTRO Clinical Practice Guidelines is presented at the ESMO Asia Virtual Oncology Week 2021
Knock-on effects of early immune checkpoint inhibitor use stimulate consideration of alternative approaches for further treatment lines
However, regulatory and financial issues will shape when and where this happens
The Pan-Asian adaptation of the ESMO guidelines introduces some changes to the standard of care in Europe, including diagnostic tests and the use of cytoreductive nephrectomy
Cost, limited drug availability and lack of diagnostic testing facilities are hurdles to adopting practice-changing recommendations in some Asian countries
Sequencing data suggest that non-G12C KRAS mutations could mediate intrinsic resistance to treatments in non-small-cell lung cancer, but functional confirmation is required
Efficacy was evaluated in AMPECT study in patients with locally advanced unresectable or metastatic malignant PEComa
Withdrawal concerns application to use Cervarix in individuals from the age of 9 years for the prevention of head and neck cancers
The results from a randomised, phase III DAWNA-1 study with a new, orally administered, selective CDK4/6 inhibitor
Results from the first prospective study showing that patients with HER2-amplified metastatic colorectal cancer identified by ctDNA genotyping benefit from dual-HER2 blockade similarly to patients identified by conventional tissue analysis
It is intended for the treatment of patients with advanced NSCLC with KRAS G12C mutation who have progressed after at least one prior line of systemic therapy
Evidence for efficacy is based on the results from the KEYNOTE-564 study
Generating high-quality evidence from registry-based studies
Evidence for efficacy is based on the results from the ASCEMBL and CABL001X2101 studies
It is indicated for treatment of adult patients with advanced NSCLC with activating EGFR Exon 20 insertion mutations, after failure of platinum-based therapy
The ESMO Immuno-Oncology Congress 2021, the European platform dedicated to the development and use of immunotherapies for cancer treatment, will be held as an onsite and online congress.
Results of the ESMO Women for Oncology monitoring and authorship studies
The much-anticipated ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer has been published today in Annals of Oncology.
Data from early clinical trials presented at the ESMO Congress 2021 suggest that new anticancer treatments are on the horizon, with a clear emphasis on precision medicine.
First concrete results presented at the ESMO Congress 2021 confirm need to promote vaccination in patients with cancer
FIRSTMAPPP, the first randomised study in malignant pheochromocytoma and paraganglioma (MPP) has found that sunitinib prolongs progression-free survival (PFS) by more than five months
The PEACE-1 and STAMPEDE studies found that the addition of abiraterone acetate plus prednisolone (AAP) to standard therapy lengthened survival compared to standard therapy alone.
Adding a CDK 4/6 inhibitor to first-line hormonal treatment prolongs survival by one year for postmenopausal women with hormone receptor (HR) positive, HER2 negative advanced breast cancer, according to late breaking results of the MONALEESA-2 trial
The addition of immunotherapy to standard first-line treatment extends survival by eight months
The collaborative study shows significant gaps in low- and middle-income countries
Experts discuss a wealth of challenges and opportunities in primary cancer prevention that oncologists themselves must take on
ESMO has announced today that the 2021 ESMO Award for Immuno-oncology is presented to Hervé Fridman
ESMO has announced today the winners of the 2021 Society Awards.
Record Impact Factor increases for ESMO journals
ESMO Congress 2021: an enhanced virtual experience
Timely presentations of trial data will accelerate transition from research to practice
Supporting your clinical decisions with ESMO’s regularly updated Clinical Practice Guidelines and consensus recommendations, developed by the leading experts in our profession.
Resources such as abstracts, presentations and webcasts from meetings can be accessed by ESMO members and conference delegates throughout all the year
The courses include state of the art lectures, workshops and interactive discussion seminars
A globally visible platform to publish scientific studies and a source of educational updates.
A range of publications that can be browsed online by all ESMO members and downloaded for offline use
Switzerland
Switzerland
Switzerland
Italy
South Africa
South Africa
Participate in our collegial events with leaders in the field and get the chance to collaborate
with prominent European cancer institutions.
Take the CME test with E-learning and V-learning modules
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.
